We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Increasing Complexity of Mercaptopurine Pharmacogenomics.
- Authors
Marsh, S.; Van Booven, D. J.
- Abstract
Thiopurine methyltransferase (TPMT) activity shows significant interindividual variation, with approximately 90% of individuals having high (wild-type) activity, 10% with intermediate activity, and 0.3% with low activity. Low and intermediate TPMT activity leads to toxicity from mercaptopurine and the need for dose reduction. Common variants in the TPMT gene have a strong association with mercaptopurine toxicity. However, recent research has shown that genetic contribution to mercaptopurine toxicity is more complex, possibly involving other genes, in particular ITPA, which encodes inosine triphosphate pyrophosphatase.Clinical Pharmacology & Therapeutics (2009); 85, 2, 139–141 doi:10.1038/clpt.2008.219
- Subjects
METHYLTRANSFERASES; CLINICAL pharmacology; CANCER treatment; DRUG dosage; CLINICAL medicine; THERAPEUTICS
- Publication
Clinical Pharmacology & Therapeutics, 2009, Vol 85, Issue 2, p139
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/clpt.2008.219